Besides, the primary immunodeficiency pathway (KEGG), CTLA4 pathway (Biocarta), and cancer immunotherapy by PD1 blockade (WP) were highly enriched in the high-risk group (Supplementary Figure S6), indicating that immune checkpoints play a role in GBM immune evasion. The gene discussed is CTLA4; the disease is cancer.